المؤلفون: Barbara Happl (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Marie Brandt (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Theresa Balber (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Katarína Benčurová (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Zeynep Talip (Center for Radiopharmaceutical Sciences, Paul Scherrer Institute), Alexander Voegele (Laboratory of Radiochemistry, Paul Scherrer Institute), Petra Heffeter (Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna), Wolfgang Kandioller (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Nicholas P. Van der Meulen (Center for Radiopharmaceutical Sciences, Paul Scherrer Institute), Markus Mitterhauser (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Marcus Hacker (Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna), Bernhard K. Keppler (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Thomas L. Mindt (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna)

المصدر: Pharmaceutics ; issn:1999-4923

مصطلحات موضوعية: ruthenium-103, BOLD-100, anti-cancer metallodrugs, in vivo studies, pharmacokinetics

وصف الملف: application/pdf

العلاقة: hdl:11353/10.2045439; https://phaidra.univie.ac.at/o:2045439Test

الإتاحة: https://doi.org/10.3390/pharmaceutics15112626Test
https://phaidra.univie.ac.at/o:2045439Test

المؤلفون: Theresa Balber (Ludwig Boltzmann Institute Applied Diagnostics), Loan Tran (Ludwig Boltzmann Institute Applied Diagnostics), Katarína Benčurová (Ludwig Boltzmann Institute Applied Diagnostics), Julia Raitanen (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Gerda Egger (Ludwig Boltzmann Institute Applied Diagnostics), Markus Mitterhauser (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna)

المصدر: Pharmaceuticals ; issn:1424-8247

مصطلحات موضوعية: molecular imaging, molecular pathology, cancer biomarkers, biomarker imaging, tracer development, in vitro models, animal models

وصف الملف: application/pdf

العلاقة: hdl:11353/10.1660552; https://phaidra.univie.ac.at/o:1660552Test

الإتاحة: https://doi.org/10.3390/ph15020227Test
https://phaidra.univie.ac.at/o:1660552Test

المؤلفون: Katarína Benčurová (Ludwig Boltzmann Institute Applied Diagnostics), Joachim Friske (Division of Molecular and Structural Preclinical Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Maximilian Anderla (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Manuela Mayrhofer (Division of Molecular and Structural Preclinical Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Thomas Wanek (Division of Molecular and Structural Preclinical Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Lukas Nics (Division of Molecular and Structural Preclinical Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Gerda Egger (Ludwig Boltzmann Institute Applied Diagnostics), Thomas H. Helbich (Division of Molecular and Structural Preclinical Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Marcus Hacker (Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Alexander Haug (Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Markus Mitterhauser (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Theresa Balber (Ludwig Boltzmann Institute Applied Diagnostics)

المصدر: Cancers ; issn:2072-6694

مصطلحات موضوعية: colorectal cancer, CXCR4, [68Ga]Ga-Pentixafor, 2-[18F]FDG, in ovo, CAM-xenograft, PET/MRI, HT29, HCT116, CRC imaging

وصف الملف: application/pdf

العلاقة: hdl:11353/10.1633024; https://phaidra.univie.ac.at/o:1633024Test

الإتاحة: https://doi.org/10.3390/cancers14225549Test
https://phaidra.univie.ac.at/o:1633024Test

المؤلفون: Carolina Giammei (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Theresa Balber (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Katarina Benčurová (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Jens Cardinale (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Neydher Berroterán-Infante (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Marie Brandt (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Nedra Jouini (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna), Marcus Hacker (Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna), Markus Mitterhauser (Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna), Thomas L. Mindt (Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna)

المصدر: Molecules ; issn:1420-3049

مصطلحات موضوعية: 99mTc-tricarbonyl, bombesin, click-to-chelate, glycation, sorbitol, pharmacological modifier, hydrophilicity, radiolabeled peptides, SPECT

وصف الملف: application/pdf

العلاقة: isPartOf:https://phaidra.univie.ac.at/o:243553Test[u:scholar collection]; hdl:11353/10.1212801; https://phaidra.univie.ac.at/o:1212801Test

الإتاحة: https://doi.org/10.3390/molecules25112680Test
https://phaidra.univie.ac.at/o:1212801Test